Bookmark and Share

Edward A. Sausville

Edward A. Sausville M.D., Ph.D.

Academic Title: Professor
Primary Appointment: Medicine
Secondary Appointments: Pharmacology
Administrative Title: Interim Division Head, Hematology & Oncology
Additional Title(s): Interim Division Chief of Hematology/Oncology; Associate Director for Clinical Research, University of Maryland Marlene & Stewart Greenebaum Cancer Center
Location: UMH Room S9D07
Phone: (410) 328-7394
Fax: (410) 328-6896

Research Interests:

I am a Medical Oncologist and Pharmacologist who joined U. Maryland School of Medicine's faculty in 2004. Prior to arriving at U. Maryland I served in the U.S. Public Health Service at the National Cancer Institute in Bethesda, Maryland. I led the National Cancer Institute's Developmental Therapeutics Program for the last 10 years of my federal service. This Program directs the NCI's preclinical anti-cancer drug development portfolio, from screening studies of potential new agents through formulation, manufacture, and safety testing for agents to enter clinical trial sponsored by NCI or grantee Institutions.

At U. Maryland I serve as the Deputy Director and Associate Director for Clinical Research of the U. Maryland Marlene & Stewart Greenebaum Cancer Center. While at U. Maryland, I chaired the Data Safety Monitoring Board for the National Lung Screening Trial, which demonstrated the value of spiral CT as screening for lung cancer in current or recent smokers.

My research interests at U. Maryland are directed at developing agents for early phase clinical trials, and then leading trials of new agents for cancer treatment. I am the Lead Investigator for U. Maryland’s affiliation with Mayo Clinic in NCI’s Experimental Therapeutics Clinical Trials Network with Phase I emphasis. My translational research interests at U. Maryland focus on developing pharmacodynamic endpoint assays for novel agents under development here.

I am Co-Editor-in-Chief of Cancer Chemotherapy Pharmacology, and am on the Editorial Boards of Molecular Cancer Therapeutics and Journal of the National Cancer Institute.


Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol, 23: 3912-22; 2005.

Acharya MR, Sparreboom A, Sausville EA, Conley BA, Doroshow JH, Venitz J, Figg WD. Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol, 57(3): 275-81; 2006.

Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res, 66:3351-4, discussion 3354; 2006.

Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE. Phase I and pharmacological study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109: 2781-90,  2007.

Borgman MP, Aras O, Geyser-Stoops S, Sausville EA, Ghandehari H. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. Mol Pharm. 6:1836-47; 2009.

Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol. 49: 1467-76; 2009.

Leamon CP, Reddy JA, Klein PJ, Vlahov IR, Dorton R, Bloomfield A, Nelson M, Westrick E, Parker N, Bruna K, Vetzel M, Gehrke M, Nicoson JS, Messmann RA, LoRusso PM, Sausville EA. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications. J Pharmacol Exp Ther 336:336-43, 2011.

Lorusso PM, Edelman MJ, Bever SL, Forman KM, Pilat M, Quinn MF, Li J, Heath EI, Malburg LM, Klein PJ, Leamon CP, Messmann RA, Sausville EA. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol. 30: 4011-6, 2012.

Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 12:809-18, 2013.

Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother Pharmacol. 72: 417-427, 2013.

Lorusso P, Venkatakrishnan K, Chiorean EG, Noe D, Wu JT, Sankoh S, Corvez M, Sausville EA.Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Invest New Drugs. 32: 160-70, 2014.

Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, Malburg L, Azad N, Cosgrove D, Knight R, Barker P, Zabludoff S, Agbo F, Oakes P, Senderowicz A.Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 73:539-49, 2014.

LoRusso PM, Goncalves PH, Casetta L, Carter JA, Litwiler K, Roseberry D, Rush S, Schreiber J, Simmons HM, Ptaszynski M, Sausville EA. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Invest New Drugs. 33:440-9, 2015.

Emadi A, Sadowska M, Carter-Cooper B, Bhatnagar V, van der Merwe I, Levis MJ, Sausville EA, Lapidus RG. Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia. Leuk Res. 39:719-29, 2015.